title: Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease.
abstract: Nonalcoholic fatty liver disease (NAFLD) is characterized by a series of pathological changes that range from simple fatty liver to nonalcoholic steatohepatitis (NASH). The objective of this study is to describe changes in global gene expression associated with the progression of human NAFLD. This study is focused on the expression levels of genes responsible for the absorption, distribution, metabolism, and elimination (ADME) of drugs. Differential gene expression between three clinically defined pathological groups-normal, steatosis, and NASH-was analyzed. Genome-wide mRNA levels in samples of human liver tissue were assayed with Affymetrix GeneChip Human 1.0ST arrays. A total of 11,633 genes exhibited altered expression out of 33,252 genes at a 5% false discovery rate. Most gene expression changes occurred in the progression from steatosis to NASH. Principal component analysis revealed that hepatic disease status was the major determinant of differential ADME gene expression rather than age or sex of sample donors. Among the 515 drug transporters and 258 drug-metabolizing enzymes (DMEs) examined, uptake transporters but not efflux transporters or DMEs were significantly over-represented in the number of genes down-regulated. These results suggest that uptake transporter genes are coordinately targeted for down-regulation at the global level during the pathological development of NASH and that these patients may have decreased drug uptake capacity. This coordinated regulation of uptake transporter genes is indicative of a hepatoprotective mechanism acting to prevent accumulation of toxic intermediates in disease-compromised hepatocytes.
authors: Department of Pharmacology and Toxicology, Tucson, AZ 85721, USA.
authors: April D
authors: AD
authors: Lake
authors: Petr
authors: P
authors: Novak
authors: Craig D
authors: CD
authors: Fisher
authors: Jonathan P
authors: JP
authors: Jackson
authors: Rhiannon N
authors: RN
authors: Hardwick
authors: D Dean
authors: DD
authors: Billheimer
authors: Walter T
authors: WT
authors: Klimecki
authors: Nathan J
authors: NJ
authors: Cherrington
mesh_terms: D000042:Absorption; D001692:Biological Transport; D018450:Disease Progression; D015536:Down-Regulation; D005234:Fatty Liver / Q000235:genetics* / Q000378:metabolism*; D015870:Gene Expression; D055106:Genome-Wide Association Study / Q000379:methods; D006801:Humans; D008099:Liver / Q000378:metabolism; D046228:Microarray Analysis / Q000379:methods; D065626:Non-alcoholic Fatty Liver Disease; D004364:Pharmaceutical Preparations / Q000378:metabolism*; D012333:RNA, Messenger / Q000235:genetics; D014018:Tissue Distribution
chemical_list: D004364:Pharmaceutical Preparations; D012333:RNA, Messenger